Provided by Tiger Trade Technology Pte. Ltd.

California Resources

52.35
-0.8900-1.67%
Post-market: 52.350.00000.00%16:04 EDT
Volume:931.62K
Turnover:48.65M
Market Cap:4.64B
PE:-37.29
High:53.06
Open:52.83
Low:51.71
Close:53.24
52wk High:71.98
52wk Low:43.25
Shares:88.60M
Float Shares:83.56M
Volume Ratio:0.96
T/O Rate:1.11%
Dividend:1.60
Dividend Rate:3.06%
EPS(TTM):-1.4038
EPS(LYR):4.15
ROE:-3.55%
ROA:0.76%
PB:1.36
PE(LYR):12.61

Loading ...

California Resources EVP, Chief Commercial Officer Jay A. Bys disposes of 11,907 shares worth $734,036.76

Reuters
·
Jun 06

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

GlobeNewswire
·
Jun 03

California Resources outlines oil and gas strategy, carbon capture growth in corporate presentation

Reuters
·
Jun 02

Does First Carbon TerraVault CO2 Injection Reshape the Bull Case for California Resources (CRC)?

Simply Wall St.
·
May 30

Analysts Are Bullish on These Energy Stocks: Canadian Natural (CNQ), California Resources Corp (CRC)

TIPRANKS
·
May 28

Abbott: ACS releases updated CRC guidelines reaffirm Cologuard, Cologuard Plus

TIPRANKS
·
May 27

California Resources price target raised to $87 from $86 at Mizuho

TIPRANKS
·
May 27

U.S. RESEARCH ROUNDUP- Agilent Technologies, Fedex, Synopsys

Reuters
·
May 27

California Resources Is Maintained at Overweight by Barclays

Dow Jones
·
May 27

Roth MKM Sticks to Their Buy Rating for California Resources Corp (CRC)

TIPRANKS
·
May 26

California Resources Corporation Achieves First CO₂ Injection at Carbon TerraVault I, a Major Milestone for Carbon Management in California

GlobeNewswire
·
May 26

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

GlobeNewswire
·
May 26

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

GlobeNewswire
·
May 22

Partner Inhibrx Reports Positive CRC Data for Ozekibart and Submits US BLA for Chondrosarcoma Treatment

Stock News
·
May 21

California Resources Raised to Buy From Neutral by Citigroup

Dow Jones
·
May 20

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

GlobeNewswire
·
May 20

BUZZ-Citigroup raises PT on US energy companies

Reuters
·
May 20

Citigroup Upgrades California Resources to Buy From Neutral, Adjusts Price Target to $78 From $74

MT Newswires Live
·
May 20

California Resources upgraded to Buy from Neutral at Citi

TIPRANKS
·
May 20

California Resources Lifts Outlook on Earnings Beat

TIPRANKS
·
May 20